7/25/2013 7:53:14 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Bristol-Myers Squibb Company (NYSE: BMY) today reported results for the second quarter of 2013 highlighted by the resubmission of Forxiga in the U.S., the completion of regulatory filings for Eliquis and Metreleptin in the U.S., and the presentation of important data from its immuno-oncology franchise at ASCO, for Orencia® at EULAR and for Eliquis at ISTH. In addition, the company adjusted GAAP EPS and non-GAAP EPS guidance for 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by